Skip to content

Weight Loss Intervention With Lean Muscle Mass Retention

Weight Loss Intervention With Lean Muscle Mass Retention (WLMR) Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05607628
Acronym
WLMR
Enrollment
100
Registered
2022-11-07
Start date
2022-07-18
Completion date
2022-12-15
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Keywords

Body Weight, Body Fat, Muscle Mass

Brief summary

Overweight and obesity (i.e., excess body fat) is a worldwide health problem, which predisposes individuals to various metabolic diseases. Weight loss through lifestyle modifications such as dietary calorie restrictions and/or exercise are effective approaches to reduce excess body fat. However, lean muscle mass loss is often an undesired outcome associated with weight loss, which should be avoided, particularly in older adults, who are also faced with declining anabolic responses to dietary protein intake. Given the increased interest and popularity of plant-based diets, in this study we will compare two distinct calorie-restricted, weight loss diets, both supplemented with weekly exercise, predominantly consisting of either plant-based proteins or animal-based proteins on changes in total body weight, body fat and lean muscle mass, as well as associated changes in metabolic health.

Detailed description

Overweight and obesity is a worldwide health problem which are linked to a plethora of age associated chronic diseases such as diabetes, cardiovascular diseases, hypertension and certain cancers. Lifestyle modifications including calorie-restricted diet and/or exercise are effective, non-invasive strategies to combat this burden. However, due to the age-associated muscle atrophy, consisting of reduced muscle functional status and anabolic resistance, calorie restriction to combat obesity is complicated by concomitant loss of skeletal muscle strength and function. Furthermore, in recent times, due to reasons of sustainability and health, there have been substantial attention on the use of alternative proteins to meet dietary protein requirements. While increased intake of animal proteins is effective in preserving lean muscle mass, to what extent they apply for plant proteins are still a matter of intense debate. Therefore, in this study we will evaluate and compare two distinct calorie restricted dietary interventions, one predominantly consisting of plant-based proteins and another predominantly consisting of animal-based proteins, both supplemented with increased exercise, on their effectiveness to reduce body fat and preserving lean muscle mass. This will be a 16 week, parallel design, randomized dietary intervention trial, in older Chinese adults, with each volunteer being provided with 2 of their 3 main meals per day, along with a mid-morning beverage, made predominantly of either plant protein or animal protein sources and being asked to undertake 3 hours of additional exercise per week. More details provided in sections below.

Interventions

COMBINATION_PRODUCTLow Calorie Animal Protein Meals

Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.

COMBINATION_PRODUCTLow Calorie Plant Protein Meals

Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.

Sponsors

Singapore Institute of Food and Biotechnology Innovation
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or Female * Chinese ethnicity * Age between 40 to 69 years * Able to give informed consent * Body Mass Index (BMI) between 23.0 to 32.5 kg/m2

Exclusion criteria

* Smoking * Having allergies or intolerances to any common food ingredients including eggs, fish, milk, peanuts, and tree nuts, shellfish, soya, wheat, gluten, cereal, fruits, dairy products, meat, vegetable, sugar and sweetener, natural food colourings or flavourings, etc * Following special diets or having intentional dietary restrictions (e.g, vegetarians/vegans) * Not willing to stop consumption of probiotic or prebiotic supplements within 4 weeks prior to start of study if currently taking these, as well as during study participation * Not willing to adhere to diet modification as in the study protocol * Not willing to adhere to the exercise regime as in the study protocol * Taking part in strenuous physical activities * Not willing to stop any strenuous activity during or within 24 hours of test days (for those actively participating in sports at the competitive and/or endurance levels) * Having glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) * Having alcohol consumption on \> 4 days per week with ≥ 6 alcoholic drinks per week * Having sustained elevation of blood pressure (\>160/95 mm Hg) * Having previously undergone any gastrointestinal surgery or having history of gastrointestinal disorders * Having a history of heart, liver, kidney, blood disorders (e.g., thalassemia) or thyroid dysfunctions * Diabetic * Having history of tuberculosis, HIV, Hepatitis B or Hepatitis C infections * Having any prescription medication or any other alternative medicines or supplements which may interfere with study measurements in the in the opinion of the study investigators * Having antibiotics or suffering from diarrhea within the last 3 months * Having donated blood within 4 weeks of study participation * Having poor veins or having history of severe vasovagal syncope (blackouts or fainting) from blood draws * Having more than 5% weight loss or gain over the past 3 months * Having metallic implants, pacemaker in the body * Having claustrophobia * Having a musculoskeletal injury, joint or peripheral vascular disease sufficient to impede exercise (such as hip arthritis, foot, ankle problems or pain) * Having severe exercise-induced asthma * Staff of Wilmar International and/or Singapore Institute of Food and Biotechnology Innovation (SIFBI) * For female volunteers: menstruation within past 12 months or being on hormone replacement therapy

Design outcomes

Primary

MeasureTime frameDescription
Body Mass16 weeks (from first to final measurement visits)kg
Body Fat %16 weeks (from first to final measurement visits)
Muscle Mass16 weeks (from first to final measurement visits)kg

Secondary

MeasureTime frameDescription
Oral glucose tolerance test16 weeks (from first to final measurement visits), measured every 8 weeksmmol/L
Blood lipid profile (HDL, LDL, Total Cholesterol, Triglyceride)16 weeks (from first to final measurement visits), measured every 4 weeksmmol/L
C-Reactive Protein16 weeks (from first to final measurement visits), measured every 8 weeksmg/L
IL-6 (Interleukin 6)16 weeks (from first to final measurement visits), measured every 8 weekspg/mL
HbA1c16 weeks (from first to final measurement visits), measured every 8 weeksmmol/mol (%)
Leptin16 weeks (from first to final measurement visits), measured every 8 weeksng/mL
β-hydroxybutyrate16 weeks (from first to final measurement visits), measured every 8 weeksmmol/L
Acetoacetate16 weeks (from first to final measurement visits), measured every 8 weeksmcg/mL
TMAO (Trimethylamine N-Oxide)16 weeks (from first to final measurement visits), measured every 8 weeksμM
TNF-α (Tumor Necrosis Factor - alpha)16 weeks (from first to final measurement visits), measured every 8 weekspg/mL
Fasting glucose16 weeks (from first to final measurement visits), measured every 4 weeksmmol/L
Fasting insulin16 weeks (from first to final measurement visits), measured every 4 weekspmol/L

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026